Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you order an OncoType DX test on a <50 year old woman with T2 N1mi HR+ HER2- breast cancer?
Answer from: Medical Oncologist at Community Practice
Yes. The patient will need chemotherapy as per RxPonder Trial.
Comments
Medical Oncologist at Hollywood Private Hospital
Is this correct? The protocol of RxPonder states-&...
Medical Oncologist at Los Angeles VA Medical Center
For micrometastases and how to interpret, please s...
7816
7819
Sign in or Register to read more
11847
Related Questions
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
How would you approach treatment for a postmenopausal patient who was treated more than 5 years ago with AC-T for TNBC, and who now presents with ipsilateral, locally advanced, node-positive TNBC, but has severe residual neuropathy from prior taxane exposure?
For patients with germline BRCA1/2 mutations, how do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
What are your top takeaways in Radiation Oncology from SABCS 2024?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
Is there data supporting the extension of adjuvant olaparib beyond one year in patients with early-stage HER2-negative breast cancer and germline BRCA1/2 mutations?
Is this correct? The protocol of RxPonder states-&...
For micrometastases and how to interpret, please s...